Because data for 2006 are still being gathered and analyzed, it is not possible to examine mid- and long-term mortality rates for those patients receiving a transplant under the LAS. However, the data provided by Hadjiliadis et al7 for a single center appear to hold true for national reports. Specifically, the percentage of transplants done for IPF increased, while transplants done for COPD decreased; PPH and CF remained roughly constant (Fig 6
). Survival data are limited by the lack of mandatory reporting between the time of discharge from the transplant admission and the 1-year posttransplant mark. As such, these preliminary data suggest a trend toward slightly increased mortality in the 2005 cohort, across all diagnosis groups. However, this trend is not statistically significant. LAS scores as reported by OPTN for transplants performed between May 4, 2005, and November 22, 2005, agree with the single-center data reported above (Fig 7
). For all diagnosis groups, the median LAS score was 36.81 at the time of transplantation. It was lowest for group B (PPH, 32.91) and highest for group D (IPF, 41.06). It should be noted, however, that these data include both lung and heart-lung transplants, rather than lung alone.